



March 1, 2023

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

We are pleased to enclose a Press Release as regards, launch of new Regional Reference Laboratory in Hyderabad, Telangana.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Hyderabad

*First Regional Reference Laboratory in South India
Targets opening 200+ collection centers in South India by March 2024*

Hyderabad, India, March 01, 2023: Global pharma major Lupin Limited (Lupin) announced today the launch of its new Regional Reference Laboratory in Hyderabad, Telangana. This expansion of Lupin Diagnostics' network is part of the company's strategy to build and strengthen its presence in South India. This regional reference laboratory adds to Lupin Diagnostics' existing network of 380+ LupiMitra collection centers and 23 laboratories across India.

Lupin Diagnostics is committed to making preventive quality healthcare accessible and affordable to all. Through the launch of this laboratory, Lupin Diagnostics will deliver high-quality and reliable diagnostic services to patients and consumers across Hyderabad and neighbouring cities.

In addition to routine and specialized tests, Lupin Diagnostics offers molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, haematology, immunology, routine biochemistry and many more. The team of qualified clinical experts at Lupin Diagnostics leverage state-of-the-art automation and streamlined processes to deliver highly accurate test results. This enables our patients to make informed decisions about their health.

"We are thrilled to continue our mission of providing accessible and affordable quality healthcare to individuals and families in India," said **Ravindra Kumar, CEO, Lupin Diagnostics**. "Diagnostics test results are crucial for doctors and patients to make informed decisions. Accurate diagnosis is the first step towards managing diseases and identifying the appropriate line of treatment. Our personalized and interactive smart reports can help doctors and patients analyse historical patterns in health parameters and guide treatment options based on evidence," **he added**.

Lupin Diagnostics provides a comprehensive range of diagnostic services to doctors, patients, and consumers. The company offers several consumer-centric features, such as live home collection booking and tracking, GPS-enabled temperature-controlled sample movement, free home collection, NABL accreditation of each laboratory, smart reports, and trend report analysis.

The company started its journey by establishing a state-of-the-art 45,000 sq. ft. National Reference Laboratory in Navi Mumbai with world-class equipment, experienced doctors assisted by trained technologists and stringent quality control protocols.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

About Lupin Diagnostics

Lupin Diagnostics Limited is a wholly owned subsidiary of Lupin Limited. Founded in October 2021, the company is headquartered in Mumbai, India and provides comprehensive range of diagnostic services to doctors, patients, and consumers.

The company began its journey by establishing a state-of-the-art 45,000 sq. ft. National Reference Laboratory located in Navi Mumbai with world-class equipment, experienced doctors assisted by trained technologists and stringent quality control protocols. Over 2,500 tests including routine and high-end tests are offered under Pathology (molecular diagnostics, cytology, microbiology, serology, hematology, histopathology, immunology, and routine biochemistry).

Currently, the company's network consists of 23 Labs, 380+ exclusive collection centers (LupiMitra), and over 1200 pick-up points.

Experience the best diagnostic experiences with Lupin Diagnostics - <https://www.lupindiagnosics.com/>

Follow us on Facebook: <https://www.facebook.com/lupindiagnosics>

Instagram: <https://www.instagram.com/lupindiagnosics/>

LinkedIn: <https://www.linkedin.com/company/lupin-diagnostics/mycompany/>

Twitter: <https://twitter.com/LupinDiagnosti1>

YouTube: <https://www.youtube.com/channel/UCbj3DVAmNdbvZayKc2XCluA>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com